Skip to main
PSNL

Personalis Inc (PSNL) Stock Forecast & Price Target

Personalis Inc (PSNL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Personalis is experiencing strong growth in its molecular clinical test volume and revenue, primarily due to the success of its NeXT Personal MRD test. Continued investments in sales and expansion in coverage for IO monitoring indication are expected to contribute to significant revenue growth in the future. Additionally, the company's focus on precision oncology and strong IP strategy make it an attractive partner for collaborations with industry leaders.

Bears say

Personalis is currently showing signs of growth in its clinical test volume and expanding its customer base, however, the company is heavily reliant on a small number of pharmaceutical partnerships for revenue and lacks diversification in its product offerings. Additionally, while the company recently obtained Medicare coverage for one of its tests, it still holds a negative cash flow position and is subject to substantial cash raises and ATM facilities to sustain operations. Overall, the company's current reliance on a small number of partnerships and its negative cash flow position make it a risky investment.

Personalis Inc (PSNL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Personalis Inc (PSNL) Forecast

Analysts have given Personalis Inc (PSNL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Personalis Inc (PSNL) has a Strong Buy consensus rating as of Jun 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Personalis Inc (PSNL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.